Multiplex Assay Kit for Pituitary Adenylate Cyclase Activating Peptide (PACAP) ,etc. by CBA (Cytometric Bead Array)
ADCYAP1; PRP-48; Pituitary Adenylate Cyclase Activating Peptide
Overview
Properties
- Product No.CMB347Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryEndocrinology
Sign into your account
Share a new citation as an author
Upload your experimental result
Review

Contact us
Please fill in the blank.
Recovery
Matrices listed below were spiked with certain level of recombinant Pituitary Adenylate Cyclase Activating Peptide (PACAP) ,etc. by CBA (Cytometric Bead Array) and the recovery rates were calculated by comparing the measured value to the expected amount of Pituitary Adenylate Cyclase Activating Peptide (PACAP) ,etc. by CBA (Cytometric Bead Array) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 94-102 | 98 |
| EDTA plasma(n=5) | 79-103 | 93 |
| heparin plasma(n=5) | 87-95 | 91 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Pituitary Adenylate Cyclase Activating Peptide (PACAP) ,etc. by CBA (Cytometric Bead Array) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Pituitary Adenylate Cyclase Activating Peptide (PACAP) ,etc. by CBA (Cytometric Bead Array) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Pituitary Adenylate Cyclase Activating Peptide (PACAP) ,etc. by CBA (Cytometric Bead Array) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 80-89% | 78-103% | 90-98% | 84-96% |
| EDTA plasma(n=5) | 97-104% | 89-99% | 97-104% | 80-90% |
| heparin plasma(n=5) | 95-103% | 96-104% | 78-91% | 80-90% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 50μL standard or sample to each well, add 50μL prepared Detection Reagent A, add 10μL magnetic beads, and incubate 90 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
5. Wash plate once on magnetic frame;
6. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
Test principle
Anti-Pituitary Adenylate Cyclase Activating Peptide (PACAP) ,etc. by CBA (Cytometric Bead Array) antibody was coated on the surface of magnetic beads. A competitive inhibition reaction is launched between biotin labeled Pituitary Adenylate Cyclase Activating Peptide (PACAP) ,etc. by CBA (Cytometric Bead Array) and unlabeled Pituitary Adenylate Cyclase Activating Peptide (PACAP) ,etc. by CBA (Cytometric Bead Array) (Standards or samples) with the pre-coated antibody specific to Pituitary Adenylate Cyclase Activating Peptide (PACAP) ,etc. by CBA (Cytometric Bead Array). PE-labeled avidin was added. The amount of bound PE conjugate is reverse proportional to the concentration of Pituitary Adenylate Cyclase Activating Peptide (PACAP) ,etc. by CBA (Cytometric Bead Array) in the sample, the intensity of MFI developed is reverse proportional to the concentration of Pituitary Adenylate Cyclase Activating Peptide (PACAP) ,etc. by CBA (Cytometric Bead Array) in the sample.
Giveaways
Increment services
Citations
- Interictal plasma pituitary adenylate cyclase-activating polypeptide levels are decreased in migraineurs but remain unchanged in patients with tension-type headachePubMed: 26296898
- Significance of serum VIP and PACAP in multiple sclerosis: an exploratory case–control study34698942
